南新制药(688189) - 2021 Q1 - 季度财报

Financial Performance - Operating revenue decreased by 23.00% to CNY 250,724,188.68 year-on-year[8] - Net profit attributable to shareholders decreased by 6.45% to CNY 24,678,193.46 compared to the same period last year[8] - Basic and diluted earnings per share decreased by 6.42% to CNY 0.1763[8] - Total operating revenue for Q1 2021 was ¥250,724,188.68, a decrease of 23.0% compared to ¥325,616,521.18 in Q1 2020[24] - Net profit for Q1 2021 was ¥25,161,556.74, compared to ¥28,512,421.77 in Q1 2020, representing a decline of 11.6%[26] - The total comprehensive income for Q1 2021 was ¥25,161,556.74, compared to ¥28,512,421.77 in Q1 2020, indicating a decrease of 11.6%[26] Cash Flow - Net cash flow from operating activities was negative at CNY -68,941,958.20, a decrease of 1,036.69% compared to the previous year[8] - Cash flow from operating activities in Q1 2021 was ¥62,624,199.09, significantly lower than ¥336,025,280.86 in Q1 2020, a drop of 81.3%[29] - The net cash flow from operating activities for Q1 2021 was ¥48,455,203.26, a significant increase compared to ¥462,886.56 in Q1 2020, reflecting a strong operational performance[33] - The company reported a total cash outflow from operating activities of ¥131,566,157.29, compared to ¥328,665,125.50 in the previous year, indicating improved cash management[30] - The net increase in cash and cash equivalents for Q1 2021 was -¥66,966,727.69, contrasting with an increase of ¥1,047,648,886.56 in Q1 2020, indicating a challenging cash flow environment[33] Assets and Liabilities - Total assets increased by 8.75% to CNY 2,268,504,632.93 compared to the end of the previous year[8] - Current assets totaled CNY 1,907,509,863.58, compared to CNY 1,713,143,799.07, reflecting an increase of about 11.34%[19] - Total liabilities rose to CNY 624,191,999.60, up from CNY 466,867,765.60, marking a significant increase of approximately 33.6%[20] - The company's equity attributable to shareholders increased to CNY 1,620,495,808.08 from CNY 1,595,817,614.62, a growth of about 1.55%[20] - Non-current assets totaled CNY 360,994,769.35, down from CNY 372,875,043.12, indicating a decrease of about 3.2%[18] Research and Development - R&D expenditure as a percentage of operating revenue increased by 4.68 percentage points to 11.43%[8] - R&D expenses increased by 30.33% to ¥28,652,554.48, indicating a boost in R&D investment[13] - Research and development expenses increased to ¥28,652,554.48 in Q1 2021, up 30.3% from ¥21,984,332.59 in Q1 2020[25] Shareholder Information - The total number of shareholders at the end of the reporting period was 7,262[11] - The largest shareholder, Hunan Xiangtou Holding Group Co., Ltd., holds 28.57% of the shares[11] Other Income and Expenses - Government subsidies recognized in the current period amounted to CNY 2,679,189.34[9] - The company reported a significant increase in other income by 1,547.30% to ¥2,679,189.34, mainly from government subsidies[13] - The company experienced a credit impairment loss of ¥-18,131,552.31 in Q1 2021, compared to ¥-2,840,994.02 in Q1 2020, reflecting a significant increase in losses[25] Investment Activities - Investment income was reported at ¥5,852,041.65, primarily from financial product returns[13] - The company reported an investment income of ¥5,852,041.65 in Q1 2021, with no comparable figure in Q1 2020[25] - Cash inflow from investment activities totaled ¥664,578,069.05, primarily driven by cash recovered from investments of ¥660,000,000.00[33] - The cash outflow for investment activities was ¥780,000,000.00, which included cash payments for investments of ¥660,000,000.00[33]